skip to main content

Alendronate administration — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardMusculoskeletal TherapeuticsAlendronate administrationGPhC CRA

A patient taking the original oval Rybelsus 14 mg tablet once daily is moved to the new round, higher-bioavailability formulation. Which new-formulation regimen gives the equivalent maintenance exposure?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — One 9 mg new-formulation tablet once daily

The new Rybelsus formulation has greater bioavailability, so lower stated strengths provide the same exposure: old 3 mg equals new 1.5 mg, old 7 mg equals new 4 mg, and old 14 mg equals new 9 mg. The correct switch is therefore one 9 mg new-formulation tablet once daily. Rybelsus remains a one-tablet-per-day medicine; combining or doubling the new tablets to reproduce the old numerical milligram value risks overdose and adverse effects.

Reference: MHRA: Rybelsus transition to the new formulation. https://www.gov.uk/drug-safety-update/rybelsus-r-semaglutide-tablets-transition-to-new-formulation-and-risk-of-medication-error